Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of DOCK5 mRNA | CTD | PMID:22206623 | 1-chloro-2,4-dinitrobenzene | affects binding | ISO | DOCK5 (Homo sapiens) | 6480464 | Dinitrochlorobenzene binds to DOCK5 protein | CTD | PMID:32991956 | 17beta-estradiol | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Estradiol results in increased expression of DOCK5 mRNA | CTD | PMID:31614463 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:31675489 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin affects the expression of DOCK5 mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of DOCK5 mRNA | CTD | PMID:33956508 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of DOCK5 mRNA | CTD | PMID:32109520 and PMID:33387578 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 2,4,6-tribromophenol | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:31675489 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 4-dinitrotoluene affects the expression of DOCK5 mRNA | CTD | PMID:21346803 | 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | tetrabromobisphenol A results in decreased expression of DOCK5 protein | CTD | PMID:31675489 | 4,4'-sulfonyldiphenol | increases expression | ISO | Dock5 (Mus musculus) | 6480464 | bisphenol S results in increased expression of DOCK5 mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of DOCK5 mRNA | CTD | PMID:28973697 | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of DOCK5 mRNA | CTD | PMID:28959563 | aflatoxin B1 | increases methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of DOCK5 exon | CTD | PMID:30157460 | all-trans-retinoic acid | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Tretinoin results in increased expression of DOCK5 mRNA | CTD | PMID:21934132 and PMID:33167477 | amiodarone | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Amiodarone results in increased expression of DOCK5 mRNA | CTD | PMID:19774075 | antirheumatic drug | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of DOCK5 mRNA | CTD | PMID:24449571 | arsane | affects methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Arsenic affects the methylation of DOCK5 gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Arsenic affects the methylation of DOCK5 gene | CTD | PMID:25304211 | arsenite(3-) | decreases methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | arsenite results in decreased methylation of DOCK5 promoter | CTD | PMID:23974009 | arsenite(3-) | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to DOCK5 mRNA] | CTD | PMID:32406909 | atrazine | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Atrazine results in increased expression of DOCK5 mRNA | CTD | PMID:22378314 | benzo[a]pyrene | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of DOCK5 mRNA | CTD | PMID:21871943 and PMID:22316170 | benzo[a]pyrene | affects methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of DOCK5 exon | CTD | PMID:30157460 | benzo[a]pyrene | increases methylation | ISO | Dock5 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased methylation of DOCK5 intron | CTD | PMID:27901495 | benzo[a]pyrene | increases methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of DOCK5 promoter | CTD | PMID:27901495 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:19150397 and PMID:20018196 | benzo[e]pyrene | decreases methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | benzo(e)pyrene results in decreased methylation of DOCK5 exon | CTD | PMID:30157460 | bis(2-ethylhexyl) phthalate | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Diethylhexyl Phthalate results in increased expression of DOCK5 mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of DOCK5 mRNA | CTD | PMID:32145629 | bisphenol A | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of DOCK5 protein | CTD | PMID:31675489 | butanal | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | butyraldehyde results in increased expression of DOCK5 mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of DOCK5 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of DOCK5 mRNA | CTD | PMID:35301059 | caffeine | decreases phosphorylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Caffeine results in decreased phosphorylation of DOCK5 protein | CTD | PMID:35688186 | calcitriol | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Calcitriol results in increased expression of DOCK5 mRNA | CTD | PMID:16002434 | CGP 52608 | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to DOCK5 gene] | CTD | PMID:28238834 | chloroprene | increases expression | ISO | Dock5 (Mus musculus) | 6480464 | Chloroprene results in increased expression of DOCK5 mRNA | CTD | PMID:23125180 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of DOCK5 mRNA | CTD | PMID:26577399 and PMID:27523638 | cyclosporin A | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of DOCK5 mRNA | CTD | PMID:25562108 | cylindrospermopsin | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | cylindrospermopsin results in increased expression of DOCK5 mRNA | CTD | PMID:24921660 | decabromodiphenyl ether | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | decabromobiphenyl ether results in decreased expression of DOCK5 protein | CTD | PMID:31675489 | dicrotophos | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | dicrotophos results in increased expression of DOCK5 mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of DOCK5 mRNA | CTD | PMID:29803840 | entinostat | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA | CTD | PMID:27188386 | entinostat | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | entinostat results in increased expression of DOCK5 mRNA | CTD | PMID:26272509 and PMID:27188386 | epoxiconazole | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of DOCK5 mRNA | CTD | PMID:35436446 | folic acid | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of DOCK5 mRNA | CTD | PMID:25629700 | formaldehyde | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of DOCK5 mRNA | CTD | PMID:23649840 | gentamycin | affects expression | EXP | | 6480464 | Gentamicins affects the expression of DOCK5 mRNA | CTD | PMID:33387578 | glyphosate | increases expression | ISO | Dock5 (Mus musculus) | 6480464 | Glyphosate results in increased expression of DOCK5 mRNA | CTD | PMID:35897073 | methapyrilene | decreases methylation | ISO | DOCK5 (Homo sapiens) | 6480464 | Methapyrilene results in decreased methylation of DOCK5 exon | CTD | PMID:30157460 | methoxychlor | affects methylation | EXP | | 6480464 | Methoxychlor affects the methylation of DOCK5 gene | CTD | PMID:35440735 | mono(2-ethylhexyl) phthalate | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | mono-(2-ethylhexyl)phthalate results in decreased expression of DOCK5 mRNA | CTD | PMID:22401849 | niclosamide | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Niclosamide results in decreased expression of DOCK5 mRNA | CTD | PMID:36318118 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of DOCK5 mRNA | CTD | PMID:25729387 | ozone | decreases expression | EXP | | 6480464 | Ozone results in decreased expression of DOCK5 mRNA | CTD | PMID:35737395 | ozone | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [Air Pollutants results in increased abundance of Ozone] which affects the expression of DOCK5 mRNA | CTD | PMID:35430440 | panobinostat | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | panobinostat results in increased expression of DOCK5 mRNA | CTD | PMID:26272509 | panobinostat | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA | CTD | PMID:27188386 | paracetamol | affects expression | ISO | Dock5 (Mus musculus) | 6480464 | Acetaminophen affects the expression of DOCK5 mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of DOCK5 mRNA | CTD | PMID:33387578 | paracetamol | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of DOCK5 mRNA | CTD | PMID:29067470 | paracetamol | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of DOCK5 mRNA | CTD | PMID:21420995 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Dock5 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of DOCK5 mRNA | CTD | PMID:36331819 | phenylmercury acetate | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of DOCK5 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA | CTD | PMID:27188386 | pirinixic acid | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of DOCK5 mRNA | CTD | PMID:19710929 | pirinixic acid | decreases expression | ISO | Dock5 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of DOCK5 mRNA | CTD | PMID:20813756 | pirinixic acid | multiple interactions | ISO | Dock5 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of DOCK5 mRNA | CTD | PMID:19710929 | potassium chromate | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of DOCK5 mRNA | CTD | PMID:22714537 | propanal | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | propionaldehyde results in increased expression of DOCK5 mRNA | CTD | PMID:26079696 | quercetin | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Quercetin results in increased expression of DOCK5 mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of DOCK5 mRNA | CTD | PMID:25895662 | sodium arsenate | increases expression | ISO | Dock5 (Mus musculus) | 6480464 | sodium arsenate results in increased expression of DOCK5 mRNA | CTD | PMID:21795629 | sodium arsenite | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of DOCK5 protein | CTD | PMID:30528433 | sunitinib | decreases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of DOCK5 mRNA | CTD | PMID:31533062 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of DOCK5 mRNA | CTD | PMID:25729387 | valproic acid | increases expression | ISO | DOCK5 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of DOCK5 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | DOCK5 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA | CTD | PMID:27188386 | |